Intra-amygdaloid microinjection of neuropeptide glutamic acid-isoleucine induces anxiety-like behavior

NeuroReport

Volumn 22, Issue 2, 2011, Pages 83-87

  Gastón, Soledad ^a   Gargiulo, Pascual A ^b   Bregonzio, Claudia ^c   Baiardi, Gustavo ^a  

^a UNIVERSIDAD CATÓLICA DE CÓRDOBA   (Argentina)

^b UNIVERSIDAD NACIONAL DE CUYO   (Argentina)

^c UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

Amygdalae; Anxiety; Corticosterone; Neuropeptide EI; Plus maze test

Indexed keywords

CORTICOSTERONE; GLUTAMIC ACID; ISOLEUCINE; NEUROPEPTIDE; NEUROPEPTIDE GLUTAMIC ACID ISOLEUCINE; UNCLASSIFIED DRUG;

ADRENAL CORTEX; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; BASOLATERAL AMYGDALA; BEHAVIOR CHANGE; BRAIN FUNCTION; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOSTERONE RELEASE; DISEASE ASSOCIATION; MALE; MAZE TEST; MICROINJECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

AMYGDALA; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CORTICOSTERONE; MALE; MICROINJECTIONS; MOTOR ACTIVITY; OLIGOPEPTIDES; RATS; RATS, WISTAR;

EID: 79551572072     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e328342b9ef     Document Type: Article

References (23)

1. Nahon JL, Presse F, Bittencourt JC, Sawchenko PE, ValeW. The rat melaninconcentrating hormone messenger ribonucleic acid encodes multiple putative neuropeptides coexpressed in the dorsolateral hypothalamus. Endocrinology 1989; 125:2056-2065.
2. Bittencourt JC, Presse F, Arias C, Peto C, Vaughan J, Nahon JL, et al. The melanin-concentrating hormone system of the rat brain: an immuno-and hybridization histochemical characterization. J Comp Neurol 1992; 319:218-245.
3. Sanchez M, Baker B, Celis ME. Melanin-concentrating hormone (MCH) antagonizes the enhancing effect of α-MSH and neuropeptide E-I on grooming and locomotor activities in the rat. Peptides 1997; 18:393-396.
4. Gonzalez MI, Baker BI, Hole DR, Wilson CA. Behavioral effects of neuropeptide E-I (NEI) in the female rat: interactions with α-MSH, MCH and dopamine. Peptides 1998; 19:1007-1016.
5. Davies M. Neural circuitry of anxiety and stress disorders. In: Davies KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: The Fifth Generation of Progress. USA: American College of Neuropsycopharmacology; 2002. pp. 931-951.
6. File SE, Zangrossi H Jr, Sanders FL, Mabbutt PS. Raised corticosterone in the rat after exposure to the elevated plus-maze. Psychopharmacology (Berl) 1994; 113:543-546.
7. Korte SM, De Boer SF. A robust animal model of state anxiety: fear-potentiated behaviour in the elevated plus-maze. Eur J Pharmacol 2003; 463:163-175.
8. Mitra R, Sapolsky RM. Acute corticosterone treatment is sufficient to induce anxiety and amygdaloid dendritic hypertrophy. Proc Natl Acad Sci U S A 2008; 105:5573-5578.
9. Roseboom PH, Nanda SA, Bakshi VP, Trentani A, Newman SM, Kalin NH. Predator threat induces behavioral inhibition, pituitary-adrenal activation and changes in amygdala CRF-binding protein gene expression. Psychoneuroendocrinology 2007; 32:44-55.
10. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. San Diego, California, USA: Academic Press; 1998.
11. Sanchez-Borzone ME, Attademo A, Baiardi G, Celis ME. Effect of betaadrenoceptors on the behaviour induced by the neuropeptide glutamic acid isoleucine amide. Eur J Pharmacol 2007; 568:186-191.
12. Sanchez MS, Barontini M, Armando I, Celis ME. Correlation of increased grooming behavior and motor activity with alterations in nigrostriatal and mesolimbic catecholamines after alpha-melanotropin and neuropeptide glutamine-isoleucine injection in the rat ventral tegmental area. Cell Mol Neurobiol 2001; 21:523-533.
13. Wall PM, Messier C. Methodological and conceptual issues in the use of the elevated plus-maze as a psychological measurement instrument of animal anxiety-like behavior. Neurosci Biobehav Rev 2001; 25:275-286.
14. Murphy BE. Some studies of the protein-binding of steroids and their application to the routine micro and ultramicro measurement of various steroids in body fluids by competitive protein-binding radioassay. J Clin Endocrinol Metab 1967; 27:973-990.
15. Bueno CH, Zangrossi H Jr, Viana MB. The inactivation of the basolateral nucleus of the rat amygdala has an anxiolytic effect in the elevated T-maze and light/dark transition tests. Braz J Med Biol Res 2005; 38:1697-1701.
16. Sutton RE, Koob GF, Le Moal M, Rivier J, Vale W. Corticotropin releasing factor produces behavioural activation in rats. Nature 1982; 297:331-333.
17. Baldwin HA, Rassnick S, Rivier J, Koob GF, Britton KT. CRF antagonist reverses the 'anxiogenic' response to ethanol withdrawal in the rat. Psychopharmacology (Berl) 1991; 103:227-232.
18. Qin M, Smith CB. Unaltered hormonal response to stress in a mouse model of fragile X syndrome. Psychoneuroendocrinology 2008; 33:883-889.
19. Oitzl MS, Van Haarst AD, De Kloet ER. Behavioral and neuroendocrine responses controlled by the concerted action of central mineralocorticoid (MRS) and glucocorticoid receptors (GRS). Psychoneuroendocrinology 1997; 22 (Suppl 1):S87-S93.
20. Bluet-Pajot MT, Presse F, Voko Z, Hoeger C, Mounier F, Epelbaum J, et al. Neuropeptide-E-I antagonizes the action of melanin-concentrating hormone on stress-induced release of adrenocorticotropin in the rat. J Neuroendocrinol 1995; 7:297-203.
21. Müller MB, Zimmermann S, Sillaber I, Hagemeyer TP, Deussing JM, Timpl P, et al. Limbic corticotropin-releasing hormone receptor 1 mediates anxietyrelated behavior and hormonal adaptation to stress. Nat Neurosci 2003; 6:1100-1107.
22. Britton KT, Lee G, Dana R, Risch SC, Koob GF. Activating and 'anxiogenic' effects of corticotropin releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasone. Life Sci 1986; 39:1281-1286.
23. Calvo N, Martijena ID, Molina VA, Volosin M. Metyrapone pretreatment prevents the behavioral and neurochemical sequelae induced by stress. Brain Res 1998; 800:227-235.